Navigation Links
Diamyd Gets Authorization to Begin Phase III Study in the US
Date:3/14/2008

STOCKHOLM, March 14 /PRNewswire-FirstCall/ -- Diamyd Medical AB (http://www.omxgroup.com, ticker: DIAM B; http://www.otcqx.com, ticker DMYDY). The FDA has given Diamyd Medical permission to start a Phase III clinical study in type 1 diabetes patients in the US with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"We are eager to start this study and to be able to offer this promising drug to our newly diagnosed type 1 diabetes patients", says Professor Jerry Palmer, University of Washington in Seattle, USA, who will be the Lead Investigator for the US study.

"We are extremely pleased with this progress," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Over the past months we have received dozens of patient inquiries with requests to participate in our Phase III type 1 diabetes studies in the US and in Europe. It is very satisfying to be able to start the studies now."

The US Phase III study will enroll 306 new-onset type 1 diabetes patients, who are within 3 months of diagnosis. Results of the study will be analyzed 15 months after all patients have been enrolled. A parallel Phase III study is planned to be conducted in Europe and together, pending a positive outcome of the trials, these pivotal studies can be used for market registration of the drug.

In a previous Phase II study in young type 1 diabetes patients, Diamyd(R) showed efficacy in preserving the patients' own insulin producing capacity for at least 30 months. No safety concerns have to date been reported in any clinical study with Diamyd(R).

Company website: http://www.diamyd.com

Diamyd Medical AB (publ). Linnegatan 89 B, SE-115 23 Stockholm, Sweden '/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Techne Corporation Announces Share Repurchase Authorization
3. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
4. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
5. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
6. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
7. ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
10. Genzyme Begins Major Expansion of Boston Manufacturing Facility
11. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual ... 2014, from 12:00 to 1:00 p.m. EDT. The session ... and practice-oriented instruction, designed for working professionals. Participants will ... their career in the biotechnology industry. , If interested ... About UMBC’s Biotechnology Graduate Programs, UMBC offers a variety ...
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty year history ... successful broadcast of a live surgery by St. Luke’s ... FAMBS, and Maher El Chaar, MD, FACS, FAMBS, using ... This sleeve gastrectomy surgery was performed and broadcast live ... surgeons from around the world during the 5th International ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the ... Industrial Average finished the day 0.12% lower at 17,049.00, and ... were broad based as seven out of ten sectors ended ... Index ended the day at 741.83, down 0.33%, while the ... has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... WILL BE FOR USE IN POINT-OF-CARE BONE MARROW PROCESSING, ... KOOL ), a leading supplier of innovative products ... said it has,received authorization from the FDA to begin ... laboratory setting or intraoperatively,for preparation of a cell concentrate ...
... water through point-of-use ... ultrafiltration, NEW ... device company, announced today that it will be exhibiting its,Dual Stage ... Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building on the ...
... July 14 Phlo Corporation,(Pink Sheets: PHCP) (the ... California of its vitality beverage, AQISS(TM),will be significantly ... of,the largest specialty beverage distributors in the San ... reached an agreement in principal with Morris,Distributing providing ...
Cached Biology Technology:ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 2ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 3ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 4Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Phlo Affiliate Announces Significant Distribution Expansion In California 2
(Date:9/15/2014)... in the Department of Science and Technology in Society ... at Virginia Tech, has won a 2014 National Science ... prospects and problems of creating a global nuclear emergency ... I Nuclear Power Plant in March 2011 was a ... emergencies, Schmid said. Three of the plant,s six nuclear ...
(Date:9/15/2014)... the oceans, there must be enough dissolved oxygen ... oxygen-starvation produces "dead zones" that decimate marine fisheries ... levels decline, energy is increasingly diverted away from ... impacts on the ecology and biogeochemistry of the ... minimum zones (OMZs) have expanded due to climate ...
(Date:9/15/2014)... and cognitive function may play roles in one,s musical ... pitch, timbre, tone durations, and formal structure in music. ... explain that extremes in musical aptitude (extreme capacity/no capacity) ... individuals having moderate aptitude. , "This is a typical ... genes, and it is influenced to varying degrees by ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... Established in 2007 and based in Toronto, ArcticDx has ... kind and specifically designed to determine one,s inherited risk ... of acquired blindness in the developed world, affecting over ... investment to undertake studies in support of a planned ...
... One of the many advantages of maintaining a normal body ... healthy heart. Fat tissue is increasingly seen as more than ... organ that normally produces high levels of a cardioprotective hormone ... has long been a mystery, and now a team led ...
... the Morrison Natural History Museum have again discovered infant ... near the town of Morrison. Dating from the Late ... made before the Rocky Mountains rose, when Morrison was ... tracks represent infant sauropods, according to discoverer Matthew Mossbrucker, ...
Cached Biology News:OGI invests in personalized medicine for age-related macular degeneration 2Study finds fat hormone's long-sought link to heart protection 2Morrison Natural History Museum discovers baby sauropod tracks 2Morrison Natural History Museum discovers baby sauropod tracks 3
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent - EDTA, 10 L...
... gel electrophoresis into an automated, high-throughput operation ... pre-cast system is ideal for analyzing multiple ... more. Fully automated, robot-compatible, and ready to ... makes your high-throughput screening assignments as easy ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: